

## Meningioma research—status quo and quo vadis

Meningiomas are the most common intracranial tumors. Most meningiomas can be cured by surgical resection and are commonly considered “an easy win” by neurooncologists, who are oftentimes confronted with more difficult tumor types such as gliomas and brain metastases (1). However, up to 20–25% of meningioma cases are not curable by surgical resection due to their location in surgically inaccessible areas such as the skull base, multifocality, or aggressive behaviour associated with higher grade histology or molecular features. Such “difficult meningiomas” have recently moved into the focus of interdisciplinary basic, translational and clinical research. With the advent of next generation sequencing technologies, our understanding of the molecular drivers of meningiomas has rapidly expanded and new clinically actionable mutations have recently been discovered (2–4). Fascinating insights have emerged and paved the way for the development of prognostically relevant classifications based on molecular data (5–11), improved application of established treatments and novel therapeutic approaches with targeted drugs. In this issue of *Chinese Clinical Oncology (CCO)* international experts provide an overview of the current knowledge and emerging perspectives in meningioma research. The topics covered include advances in histopathological and molecular classification, radiotherapy, surgery, and animal models of meningioma. Without doubt, meningioma research has become one of the most dynamically evolving fields of neurooncology and is producing insights that benefit our patients. Importantly, several prospective international clinical trials enrolling patients with aggressive or recurrent meningiomas are ongoing and will likely provide us with more effective therapies (*Table 1*). As we continue to explore novel therapeutic approaches, and expand and validate molecular classifications of meningiomas, the paradigm of meningioma diagnosis and management will change.

### Acknowledgements

None.


### References

1. Goldbrunner R, Minniti G, Preusser M, et al. EANO guidelines for the diagnosis and treatment of meningiomas. *Lancet Oncol* 2016;17:e383–91.
2. Brastianos PK, Horowitz PM, Santagata S, et al. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. *Nat Genet* 2013;45:285–9.
3. Clark VE, Erson-Omay EZ, Serin A, et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. *Science* 2013;339:1077–80.
4. Sahm F, Bissel J, Koelsche C, et al. AKT1E17K mutations cluster with meningotheial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry. *Acta Neuropathol* 2013;126:757–62.
5. Abedalthagafi M, Bi WL, Aizer AA, et al. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. *Neuro Oncol* 2016;18:649–55.

**Table 1** Selected prospective clinical trials enrolling meningioma patients

Trial	Patient population	Treatment regimen	Number of patients
Alliance A071401 (PI Brastianos)	Grade I, II, III meningiomas with mutations in SMO, AKT, NF2	SMO, AKT, FAK inhibitor for meningiomas harboring SMO, AKT, NF2 mutations respectively	84
EORTC-1320-BTG (PI Preusser)	Grade II or III meningiomas with no treatment options	Trabectedin vs. best investigator’s choice	86
ROAM/EORTC-1308 (PI Jenkinson)	Grade II meningiomas undergoing gross total resection	Adjuvant radiation vs. observation	190

6. Sahm F, Schrimpf D, Olar A, et al. TERT Promoter Mutations and Risk of Recurrence in Meningioma. *J Natl Cancer Inst* 2015;108.
7. Sahm F, Schrimpf D, Stichel D, et al. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. *Lancet Oncol* 2017;18:682-94.
8. Shankar GM, Abedalthagafi M, Vaubel RA, et al. Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. *Neuro Oncol* 2017;19:535-45.
9. Strickland MR, Gill CM, Nayyar N, et al. Targeted sequencing of SMO and AKT1 in anterior skull base meningiomas. *J Neurosurg* 2016:1-7.
10. Du Z, Abedalthagafi M, Aizer AA, et al. Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. *Oncotarget* 2015;6:4704-16.
11. Reuss DE, Piro RM, Jones DT, et al. Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations. *Acta Neuropathol* 2013;125:351-8.



Matthias Preusser, MD



Priscilla Brastianos, MD



Helen A Shih, MD

**Matthias Preusser, MD**

*Department of Medicine I, Comprehensive Cancer Center CNS Unit (CCC-CNS), Medical University of Vienna, Wien, Austria. (Email: matthias.preusser@meduniwien.ac.at)*

**Priscilla Brastianos, MD**

*Departments of Medicine and Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. (Email: pbrastianos@partners.org)*

**Helen A Shih, MD**

*Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA. (Email: HSHIH@partners.org)*

doi: 10.21037/cco.2017.06.21

*Conflicts of Interest:* The authors have no conflicts of interest to declare.

**View this article at:** <http://dx.doi.org/10.21037/cco.2017.06.21>

**Cite this article as:** Preusser M, Brastianos P, Shih HA. Meningioma research—status quo and quo vadis. *Chin Clin Oncol* 2017;6(Suppl 1):S1. doi: 10.21037/cco.2017.06.21